Zidovudine has proved to be an important palliative agent in all stages of HIV infection. It delays progression of disease in patients with asymptomatic or mildly symptomatic infection and decreases the frequency and severity of opportunistic disease in those with AIDS. The search for other, more effective antiretroviral agents goes on, with some promising possibilities.